Foresite Capital Management IV, LLC holds a concentrated book of 8 stocks worth $237.1M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Eikon Therapeutics Inc and trimmed Maze Therapeutics Inc. Their largest long position is Pharvaris NV at 57% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1704132/holdings"
Use Arkolith to show Foresite Capital Management IV, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Foresite Capital Management IV, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 8 / 8 | $1.7B |
| FMR LLC | 8 / 8 | $1.6B |
| STATE STREET CORP | 8 / 8 | $570.0M |
| GEODE CAPITAL MANAGEMENT, LLC | 8 / 8 | $342.0M |
| Ken Griffin | 8 / 8 | $267.5M |
| BANK OF AMERICA CORP /DE/ | 8 / 8 | $249.4M |
| GOLDMAN SACHS GROUP INC | 8 / 8 | $232.8M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 8 / 8 | $227.8M |
Ranked by how many of Foresite Capital Management IV, LLC's top 8 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Pharvaris N.V. COM | $135.0M | 4.78M | 56.9% | —Held | |
| 2 | Cytokinetics Inc COM | $33.2M | 503.3K | 14.0% | ▲+9.8% Added · +45K sh | |
| 3 | Eikon Therapeutics, Inc. COM | $20.6M | 1.94M | 8.7% | ▲New New position | |
| 4 | Lyell Immunopharma, Inc. COM | $16.1M | 800.4K | 6.8% | —Held | |
| 5 | Relay Therapeutics, Inc. COM | $9.9M | 1.00M | 4.2% | —Held | |
| 6 | Xenon Pharmaceuticals Inc. COM | $9.3M | 160.0K | 3.9% | —Held | |
| 7 | Alector, Inc. COM | $8.4M | 3.89M | 3.5% | —Held | |
| 8 | Maze Therapeutics, Inc. COM | $4.7M | 156.9K | 2.0% | ▼−70% Reduced · −366K sh |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.